Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 47

Results For "vaccine"

967 News Found

AGC invests US$ 348 million to expand its biopharmaceutical CDMO capability
News | December 21, 2023

AGC invests US$ 348 million to expand its biopharmaceutical CDMO capability

Development services for gene and cell therapies is planned to begin first in 2025

FDA grants priority review to Merck’s new biologics license application for V116
Drug Approval | December 20, 2023

FDA grants priority review to Merck’s new biologics license application for V116

V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults

Panacea Biotec launches EasyFourPol in India
News | December 17, 2023

Panacea Biotec launches EasyFourPol in India

Receives registration of Valganciclovir powder for oral solution in Germany

Moderna Chief Commercial Officer steps down, President to look over pipeline strategy
People | December 14, 2023

Moderna Chief Commercial Officer steps down, President to look over pipeline strategy

Announces changes to commercial organization to prepare for multiple product launches in 2024 and 2025

Pfizer receives regulatory approvals to complete the acquisition of Seagen
News | December 13, 2023

Pfizer receives regulatory approvals to complete the acquisition of Seagen

Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution

New global survey finds widespread misunderstandings about shingles despite its lifetime prevalence
News | December 01, 2023

New global survey finds widespread misunderstandings about shingles despite its lifetime prevalence

A new GSK survey shows a large number of adults do not understand how shingles may be triggered

DxVx plans to make a license-in agreement of OVM-200
News | November 25, 2023

DxVx plans to make a license-in agreement of OVM-200

Final stage in licensing OVM-200 from Oxford Vacmedix in the UK

GSK registers 5% revenue growth in Q2 FY24
News | November 10, 2023

GSK registers 5% revenue growth in Q2 FY24

General Medicine grows 5% and Vaccines 10% led by Shingrix

Evonik launches GMP-quality plant-based squalene
News | November 08, 2023

Evonik launches GMP-quality plant-based squalene

PhytoSquene now available for clinical and commercial use

Indian pharmaceutical companies have become reliable and affordable suppliers of high-quality drugs: MoS Bhagwant Khuba
Policy | November 08, 2023

Indian pharmaceutical companies have become reliable and affordable suppliers of high-quality drugs: MoS Bhagwant Khuba

Lack of technology transfer stands out as a formidable barrier

Latest Stories

iRegene’s Parkinson’s therapy gains FDA designation

AstraZeneca gains full global rights to AbelZeta’s CAR-T therapy in $630M deal

Brenig Therapeutics launches first-in-human trial of novel neurodegenerative therapy

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging